Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Grupp K, Sanader S, Sirma H, Simon R, Koop C, Prien K, Hube-Magg C, Salomon G, Graefen M, Heinzer H, Minner S, Izbicki JR, Sauter G, Schlomm T, Tsourlakis MC. Grupp K, et al. Among authors: koop c. Mol Oncol. 2013 Dec;7(6):1001-11. doi: 10.1016/j.molonc.2013.07.009. Epub 2013 Jul 19. Mol Oncol. 2013. PMID: 23941784 Free PMC article.
High mitochondria content is associated with prostate cancer disease progression.
Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Schlomm T, Minner S, Steurer S. Grupp K, et al. Among authors: koop c. Mol Cancer. 2013 Nov 21;12(1):145. doi: 10.1186/1476-4598-12-145. Mol Cancer. 2013. PMID: 24261794 Free PMC article.
The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A. Grupp K, et al. Among authors: koop c. Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778. Epub 2014 Feb 26. Int J Cancer. 2014. PMID: 24510842 Free article.
NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A. Grupp K, et al. Among authors: koop c. Prostate. 2014 Jul;74(10):1012-22. doi: 10.1002/pros.22816. Epub 2014 May 1. Prostate. 2014. PMID: 24789172
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C, Barreau Y, Simon R, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Sauter G, Wittmer C, Steurer S, Adam M, Huland H, Schlomm T, Tsourlakis MC, Quaas A. Burdelski C, et al. Among authors: koop c. Hum Pathol. 2015 Apr;46(4):514-23. doi: 10.1016/j.humpath.2014.06.006. Epub 2014 Jun 26. Hum Pathol. 2015. PMID: 25701228
Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.
Burdelski C, Strauss C, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Krech T, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S. Burdelski C, et al. Among authors: koop c. Oncotarget. 2015 Apr 10;6(10):8377-87. doi: 10.18632/oncotarget.3107. Oncotarget. 2015. PMID: 25762627 Free PMC article.
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Burdelski C, Ruge OM, Melling N, Koop C, Simon R, Steurer S, Sauter G, Kluth M, Hube-Magg C, Minner S, Wittmer C, Wilczak W, Hinsch A, Lebok P, Izbicki JR, Heinzer H, Graefen M, Huland H, Schlomm T, Krech T. Burdelski C, et al. Among authors: koop c. Exp Mol Pathol. 2015 Jun;98(3):419-26. doi: 10.1016/j.yexmp.2015.03.024. Epub 2015 Mar 18. Exp Mol Pathol. 2015. PMID: 25794974
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Zabalza CV, Adam M, Burdelski C, Wilczak W, Wittmer C, Kraft S, Krech T, Steurer S, Koop C, Hube-Magg C, Graefen M, Heinzer H, Minner S, Simon R, Sauter G, Schlomm T, Tsourlakis MC. Zabalza CV, et al. Among authors: koop c. Oncotarget. 2015 May 20;6(14):12822-34. doi: 10.18632/oncotarget.3431. Oncotarget. 2015. PMID: 25825985 Free PMC article.
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC, Khosrawi P, Weigand P, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Krech T, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S. Tsourlakis MC, et al. Among authors: koop c. Int J Mol Sci. 2015 Apr 16;16(4):8591-606. doi: 10.3390/ijms16048591. Int J Mol Sci. 2015. PMID: 25894226 Free PMC article.
Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, Steurer S. Burdelski C, et al. Among authors: koop c. Clin Cancer Res. 2015 Aug 1;21(15):3471-9. doi: 10.1158/1078-0432.CCR-14-0620. Epub 2015 Apr 29. Clin Cancer Res. 2015. PMID: 25925890
349 results